SINO BIOPHARM: 2025 INTERIM REPORT

Sino Biopharm achieved revenue of RMB 17.57 billion in the first half of 2025, representing a year-on-year increase of 10.7%; profit attributable to parent company owners reached RMB 3.39 billion, reflecting a year-on-year growth of 140.2%. Revenue from innovative products amounted to RMB 7.8 billion, growing by 27.2% year-on-year and accounting for 44.4% of total revenue. During the period, R&D investment totaled RMB 3.19 billion, representing 18.1% of revenue. The board declared an interim dividend of 5 Hong Kong cents per share.During the period, the company received NMPA approval for two innovative products: Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). Revenue from the oncology sector reached RMB 6.69 billion, increasing by 24.9% year-on-year; revenue from surgery/pain...Show More

Sino Biopharm achieved revenue of RMB 17.57 billion in the first half of 2025, representing a year-on-year increase of 10.7%; profit attributable to parent company owners reached RMB 3.39 billion, reflecting a year-on-year growth of 140.2%. Revenue from innovative products amounted to RMB 7.8 billion, growing by 27.2% year-on-year and accounting for 44.4% of total revenue. During the period, R&D investment totaled RMB 3.19 billion, representing 18.1% of revenue. The board declared an interim dividend of 5 Hong Kong cents per share.During the period, the company received NMPA approval for two innovative products: Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). Revenue from the oncology sector reached RMB 6.69 billion, increasing by 24.9% year-on-year; revenue from surgery/pain management drugs was RMB 3.11 billion, up by 20.2% year-on-year. The company continued to increase its R&D investments, with a total of 37 innovative drug candidates in clinical or advanced development stages in the oncology field as of the reporting period.The company actively advanced its global strategic cooperation initiatives, announcing in July 2025 the acquisition of Limin Pharmaceuticals for a net consideration of USD 500 million to further enhance its innovative R&D capabilities. Over the next three years (2025-2027), nearly 20 innovative products are expected to be approved for market launch, more than half of which are anticipated to achieve peak sales exceeding RMB 2 billion each. The company will continue to focus on innovation, improve R&D efficiency and quality across its four therapeutic areas, and accelerate its international expansion.